NDC product
EPIOXA CROSS-LINKING
NDC 25357-024 · Glaukos Corporation
Key facts
| Product NDC | 25357-024 |
|---|---|
| Proprietary name | EPIOXA CROSS-LINKING |
| Nonproprietary name | riboflavin 5-phosphate ophthalmic |
| Dosage form | KIT |
| Route | OPHTHALMIC |
| Labeler | Glaukos Corporation |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA219910 |
| Marketing start | Jan 16, 2026 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: